Kenneth Erland Johnson - 31 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Senior Vice President, Global Development and Medical Affairs
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2025
Net transactions value
-$147,092
Form type
4
Filing time
03 Feb 2025, 19:39:11 UTC
Previous filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $55,095 -15,476 -4.3% $3.56 346,288 31 Jan 2025 Direct F1
transaction XERS Common Stock Tax liability $91,998 -25,842 -7.5% $3.56 320,446 31 Jan 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.

Remarks:

Senior Vice President, Global Development and Medical Affairs